We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+3.9%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$270M
AUM Growth
-$974K
Cap. Flow
+$3.47M
Cap. Flow %
1.29%
Top 10 Hldgs %
48.55%
Holding
70
New
8
Increased
19
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$7.67M
2
AMGN icon
Amgen
AMGN
+$7.52M
3
INSM icon
Insmed
INSM
+$6.87M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.37M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$8.83M
2
AERI
Aerie Pharmaceuticals
AERI
+$7.18M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$5.83M
4
WVE icon
Wave Life Sciences
WVE
+$5.63M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$5.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNTA
51
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$997K 0.37%
80,000
+25,420
+47% +$338K
ARNA
52
DELISTED
Arena Pharmaceuticals Inc
ARNA
$967K 0.36%
16,500
– –
KYNB
53
Kyntra Bio
KYNB
$32.4M
$889K 0.33%
788
– –
CNCE
54
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$839K 0.31%
+70,000
New +$753K
LGND icon
55
Ligand Pharmaceuticals
LGND
$5.67B
$833K 0.31%
11,702
– –
TCDA
56
DELISTED
Tricida, Inc. Common Stock
TCDA
$788K 0.29%
20,000
+934
+5% +$32.8K
AKCA
57
DELISTED
Akcea Therapeutics Inc
AKCA
$743K 0.28%
31,723
-42,885
-57% -$1.06M
FOLD
58
DELISTED
Amicus Therapeutics
FOLD
$730K 0.27%
58,600
– –
ZGNX
59
DELISTED
Zogenix, Inc.
ZGNX
$687K 0.25%
14,400
-78,600
-85% -$3.17M
SUPN icon
60
Supernus Pharmaceuticals
SUPN
$2.57B
$659K 0.24%
19,953
-70,000
-78% -$2.4M
PRQR icon
61
ProQR Therapeutics
PRQR
$327M
$511K 0.19%
+56,000
New +$661K
RDUS
62
DELISTED
Radius Health, Inc.
RDUS
$414K 0.15%
17,000
-88,829
-84% -$1.94M
TVTX icon
63
Travere Therapeutics
TVTX
$6.36B
$362K 0.13%
18,000
-190,000
-91% -$3.75M
DERM
64
DELISTED
Dermira, Inc.
DERM
$287K 0.11%
30,000
– –
ENTA icon
65
Enanta Pharmaceuticals
ENTA
$402M
– –
-61,000
Closed -$5.83M
IFRX icon
66
InflaRx
IFRX
$335M
– –
-32,500
Closed -$1.22M
MGNX icon
67
MacroGenics
MGNX
$260M
– –
-19,000
Closed -$342K
WVE icon
68
Wave Life Sciences
WVE
$1.02B
– –
-145,000
Closed -$5.63M
AERI
69
DELISTED
Aerie Pharmaceuticals
AERI
– –
-151,117
Closed -$7.18M
ARRY
70
DELISTED
Array Biopharma Inc
ARRY
– –
-72,500
Closed -$1.77M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2019 Portfolio in Review

As of Q2 2019, International Biotechnology Trust held 70 positions worth $270M, down 0.36% from $271M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

International Biotechnology Trust's Q2 2019 filing shows 8 new, 19 increased, 15 reduced and 6 closed positions. Its largest new stake was uniQure: 27,500 shares worth $2.15M. The largest sale was Celgene Corp, an estimated $8.83M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q2 2019 buy was uniQure: 27,500 shares worth $2.15M.
  • International Biotechnology Trust added most to Biogen in Q2 2019, an estimated $7.67M increase.
  • International Biotechnology Trust's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $8.83M.
  • International Biotechnology Trust fully exited Aerie Pharmaceuticals in Q2 2019, selling an estimated $7.18M.
  • International Biotechnology Trust's ten largest holdings make up 49% of its $270M portfolio in Q2 2019.
  • International Biotechnology Trust opened 8 new positions and closed 6 in Q2 2019.
  • International Biotechnology Trust's portfolio value fell 0.36% quarter-over-quarter to $270M.

Based on International Biotechnology Trust's 13F filing for Q2 2019, filed 14 Aug 2019.